Esther Elishaev

ORCID: 0000-0002-6271-0222 · 50 papers in corpus
lab-animal 2023
·doi:10.1158/1078-0432.22455182.v1

Suppl Fig S4. Complement and non-target siRNA

lab-animal 2023
·doi:10.1158/1078-0432.22455182

Suppl Fig S4. Complement and non-target siRNA

2023
·doi:10.1158/1078-0432.22455179.v1

Suppl Table S1. Differentially expressed genes from different group comparisons

2023
·doi:10.1158/1078-0432.22455179

Suppl Table S1. Differentially expressed genes from different group comparisons

2023
·doi:10.1158/1078-0432.22455176.v1

Suppl Table S2. Top five canonical pathways from different group comparisons, identified via Ingenuity Pathway Analyses

2023
·doi:10.1158/1078-0432.22455176

Suppl Table S2. Top five canonical pathways from different group comparisons, identified via Ingenuity Pathway Analyses

2023
·doi:10.1158/1078-0432.22455173.v1

Suppl Table S3. Top five networks from different group comparisons, identified via Ingenuity Pathway Analyses

2023
·doi:10.1158/1078-0432.22455173

Suppl Table S3. Top five networks from different group comparisons, identified via Ingenuity Pathway Analyses

other 2022
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.epi-21-0677

BACKGROUND: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biologica…

lab-animal 2022
Cancer research ·doi:10.1158/0008-5472.CAN-22-1294

UNLABELLED: Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem ce…

observational 2022
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.CCR-21-3817

PURPOSE: To identify molecular subclasses of clear cell ovarian carcinoma (CCOC) and assess their impact on clinical presentation and outcomes. EXPERIMENTAL DESIGN: We profiled 421 primary CCOCs that passed quality control using a targeted…

observational 2021
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

observational 2021
The Journal of Pathology ·doi:10.1002/path.5849

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on i…

observational 2019
Nature communications ·doi:10.1038/s41467-019-10979-3

Tumor-driven immune suppression is a major barrier to successful immunotherapy in ovarian carcinomas (OvCa). Among various mechanisms responsible for immune suppression, arginase-1 (ARG1)-carrying small extracellular vesicles (EVs) emerge a…

2018
·doi:10.1158/1557-3265.ovca17-b23

Abstract Objectives: To investigate changes in estrogen receptor–alpha (ERα) signaling during the progression of endometriosis to endometriosis-associated ovarian cancer (EAOC) as a putative driver of malignant transformation. Methods: We p…

other 2018
Hormones & cancer ·doi:10.1007/s12672-018-0350-9

To investigate changes in estrogen receptor alpha (ERα) signaling during progression of endometriosis to endometriosis-associated ovarian cancer (EAOC) as a driver of malignant transformation. We procured tissue samples of normal endometriu…

review 2017
Annals of clinical and laboratory science

Unusual variants of endometrial endometrioid adenocarcinoma can be diagnostically challenging and pose difficulties to differentiate from their benign and malignant mimickers. Here we describe an entity that has been well documented in the …

review 2016
Expert review of molecular diagnostics ·doi:10.1080/14737159.2016.1194758

INTRODUCTION: Ovarian cancer (OvCa) is among the most common types of cancer and is the leading cause of death from gynecological malignancies in western countries. Cancer biomarkers have a potential for improving the management of OvCa pat…

2016
·doi:10.1016/j.ygyno.2016.04.305
lab-animal 2014
·doi:10.1158/1538-7445.am2014-1653

Abstract Introduction: Endometriosis is a largely benign, chronic inflammatory disease defined by the presence of endometrial-like glands surrounded by stroma. Epidemiologic studies suggest that endometriosis is an independent risk factor f…

other 2014
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-14-1338

PURPOSE: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian tumors p…

lab-animal 2014
PloS one ·doi:10.1371/journal.pone.0102409

Activating mutations of Kras oncogene and deletions of Pten tumor suppressor gene play important roles in cancers of the female genital tract. We developed here new preclinical models for gynecologic cancers, using conditional (Cre-loxP) mi…

2014
·doi:10.4049/jimmunol.192.supp.203.39

Abstract Endometriosis is a largely benign, chronic inflammatory disease that may predispose to some of the ovarian tumors histotypes, collectively called endometriosis-associated ovarian cancers (EAOC). Although it is widely accepted that …

rct 2013
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.ccr-12-2726

PURPOSE: Endometriosis, a largely benign, chronic inflammatory disease, is an independent risk factor for endometrioid and clear cell epithelial ovarian tumors. We aimed to identify plasma miRNAs that can be used to differentiate patients w…

observational 2010
·doi:10.1158/1538-7445.am10-1335

Abstract Objective: Examine the expression and immunogenicity of a known ovarian tumor-associated antigen, MUC1, in ectopic endometriosis lesions and epithelial ovarian cancer (EOC). Determine whether an imbalance in CD4 T cell subsets cont…